CD133 expression: A potential prognostic marker for non-small cell lung cancers

International Journal of Clinical Oncology

Volumn 19, Issue 2, 2014, Pages 254-259

  Mizugaki, Hidenori ^a   Sakakibara Konishi, Jun ^a   Kikuchi, Junko ^a   Moriya, Jun ^b   Hatanaka, Kanako C ^b   Kikuchi, Eiki ^a   Kinoshita, Ichiro ^c   Oizumi, Satoshi ^a   Dosaka Akita, Hirotoshi ^c   Matsuno, Yoshihiro ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD133; Immunohistochemical assessment; Non small cell lung cancer; Prognostic marker

Indexed keywords

CD133 ANTIGEN; TUMOR MARKER; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOLID TUMOR; CHEMISTRY; LUNG TUMOR; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84899967059     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0541-x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Miraglia S, Godfrey W, Yin AH et al (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013-5021 (Pubitemid 28007218)
3. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature (Lond) 445:111-115 (Pubitemid 46067311)
4. Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature (Lond) 432:396-401 (Pubitemid 39551674)
5. Horst D, Kriegl L, Engel J et al (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99:1285-1289
6. Zeppernick F, Ahmadi R, Campos B et al (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123-129 (Pubitemid 351377986)
7. Zhao P, Li Y, Lu Y (2010) Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 10:218
8. Song W, Li H, Tao K et al (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62:1212-1218 (Pubitemid 351977611)
9. Salnikov AV, Kusumawidjaja G, Rausch V et al (2009) Cancer stem cell marker expression in hepatocellular carcinoma and liver metastasis is not sufficient as single prognostic parameter. Cancer Lett 275:185-193
10. Donnenberg VS, Landreneau RJ, Donnenberg AD (2007) Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J Control Release 122:385-391 (Pubitemid 47404670)
11. Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133? cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281-16286
12. Woo T, Okudela K, Mitsui H et al (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4:32-42
13. Zhang HZ, Wei YP, Wang M et al (2007) Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 27:696-699
14. Salnikov AV, Gladkich J, Moldenhauer G et al (2010) CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 126:950-958
15. Li F, Zeng H, Ying K (2010) The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 28:1458-1462
16. Beahrs O, Henson D, Hutter R et al (1992) AJCC manual for staging of cancer, lung. Lippincott, Philadelphia
17. Hermansen SK, Christensen KG, Jensen SS et al (2011) Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59:391-407
18. Sasaki A, Kamiyama T, Yokoo H et al (2010) Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep 24:537-546
19. Sagrinati C, Netti GS, Mazzinghi B et al (2006) Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 17:2443-2456 (Pubitemid 44300960)
20. Hilbe W, Dirnhofer S, Oberwasserlechner F et al (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965-969 (Pubitemid 39208249)
21. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:1253-1261 (Pubitemid 44427449)
22. Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature (Lond) 414:105-111 (Pubitemid 33041634)
23. Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951 (Pubitemid 41713363)
24. Suetsugu A, Nagaki M, Aoki H (2006) Characterization of CD133? hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820-824 (Pubitemid 44715858)
25. Eramo A, Lotti F, Sette G et al (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504-514 (Pubitemid 351267301)
26. Horst D, Scheel SK, Liebmann S et al (2009) The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219:427-434
27. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768
28. Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133? and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111-2120 (Pubitemid 351872330)
29. Janikova M, Skarda J, Dziechciarkova M et al (2010) Identification of CD133?/nestin ? putative cancer stem cells in nonsmall cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:321-326